Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Stockholders Equity of $18.67 billion for fiscal year 2025.
VERTEX PHARMACEUTICALS INC / MA Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $18.67B | +13.7% |
| 2024 | $16.41B | -6.7% |
| 2023 | $17.58B | +26.4% |
| 2022 | $13.91B | +37.7% |
| 2021 | $10.10B | +16.3% |
| 2020 | $8.69B | +42.8% |
| 2019 | $6.09B | +37.2% |
| 2018 | $4.44B | +118.6% |
| 2017 | $2.03B | +75.4% |
| 2016 | $1.16B | +23.0% |
| 2015 | $939.97M | -12.6% |
| 2014 | $1.08B | -20.7% |
| 2013 | $1.36B | +35.8% |
| 2012 | $999.18M | +27.0% |
| 2011 | $786.84M | +56.1% |
| 2010 | $503.97M | -54.0% |
| 2009 | $1.10B | +359.0% |
| 2008 | $238.87M | -12.0% |
| 2007 | $271.30M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.32B | +10.8% | +0.8% |
| June 30, 2025 | $17.18B | +16.2% | +4.1% |
| March 31, 2025 | $16.50B | -11.1% | +0.5% |
| December 31, 2024 | $16.41B | -6.7% | +5.0% |
| September 30, 2024 | $15.63B | -5.3% | +5.8% |
| June 30, 2024 | $14.77B | -4.5% | -20.3% |
| March 31, 2024 | $18.55B | +28.5% | +5.5% |
| December 31, 2023 | $17.58B | +26.4% | +6.5% |
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +13.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2007–2025 period, VERTEX PHARMACEUTICALS INC / MA’s stockholders equity has grown by 6780.3% (from $271.30 million to $18.67 billion).
- The most recent figure is from VERTEX PHARMACEUTICALS INC / MA’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: